CURE Pharmaceutical Delivering the Promise of Healthier Lives

OTCQB: CURR

January 2019

AUGUST 2018

To the extent any statements made in this presentation contains forward looking statements and information that are based upon beliefs of, and information currently available to, the company’s management as well as estimates and assumptions made by the company’s management. When used in this presentation the words “anticipate,” “believe,” “estimate,” “expect,” “future,” “intend,” “plan” or the negative of these terms and similar expressions as they relate to the company or the company’s management identify forward looking statements.

Such statements reflect the current view of the company with respect to future events and are subject to risks, uncertainties, assumptions and other factors relating to the company’s industry, its operations and results of operations and any businesses that may be acquired by the company. Should one or more of these risks or uncertainties materialize, or should the underlying assumptions prove incorrect, actual results may differ significantly from those anticipated, believed, estimated, expected, intended or planned.

Although the company believes that the expectations reflected in the forward looking statements are reasonable, the company cannot guarantee future results, levels of activity, performance or achievements. Except as required by applicable law, including the securities laws of the United States, the company does not intend to update any of the forward-looking statements to conform these statements to actual results.

In order for drugs to work, three factors must be carefully balanced:

EFFICACY SAFETY ADHERENCE

Enough drug must Too much drug in Patients must get into the body the body can cause take their drugs to be effective. serious side effects. as prescribed.

With drug loss at each step, higher doses of Many orally delivered drugs can cause oral drugs are often needed to achieve the GI irritation such as constipation, therapeutic benefit. diarrhea and pain or damage the liver.

This especially impacts poorly soluble drugs Many drugs never make it to market that are otherwise permeable to cells. because the efficacious dose causes toxicities. 30% of drugs on the market and 70% or drugs in the pipeline fall into this category.*

Patients suffer when drugs work too slowly or lack sufficient efficacy. $630B Annual global revenues lost in pharma from medication non-adherence.* Lack of efficacy combined with side effects often deter patients from taking their medication as prescribed. $100B Additional US healthcare costs from related hospitalizations due to non-adherence

Alternative oral routes of delivery impact drug efficacy, safety and the patient experience.

● Sublingual delivery - under the tongue ● Buccal delivery - between cheek and gum

Sublingual and buccal drug delivery lead to direct absorption into the bloodstream avoiding:

● The need to swallow a pill ● Drug exposure to stomach acids and tissue irritation ● Drug absorption through the intestines ● Liver metabolism and potential injury

With our technology, we can deliver drugs more safely and efficaciously by using:

● THE RIGHT FORMULATION improves a drug’s solubility

● THE RIGHT DOSAGE FORM changes its route of administration

WHO WE ARE We are a drug delivery and development company with a proprietary formulation and delivery platform - CUREfilm.TM

WHAT WE DO We improve pharmacokinetics of small molecules for easier, safer and more effective administration.

HOW WE DO IT We partner with innovative companies to improve investigational and marketed drugs and dietary supplements.

A proprietary multivalent formulation platform that creates compositions with optimal drug release profiles for better patient outcomes and experiences.

OUR TOOLBOX • Encapsulants • Stabilizers • Plasticizers • Permeation enhancers • Mucoadhesive agents • Layering methods • Flavorings Microscopic view of encapsulated active in CUREfilm Oral strip

Our formulations can be used in multiple final dosage forms based on the desired drug release profile and patient experience.

CUREFILM™ CUREFILM™ ORAL TRANSDERMAL

● Buccal ● Transdermal gel ● Sublingual ● Patch ● Enteric

Customizable Fast Symptom Relief Fewer Side Effects Multiple active Rapid and/or sustained Potential to reduce the dose ingredients in one dose delivery of active ingredients and avoid the GI tract

No Pills to Swallow Quick Dissolve Portable Ideal for consumers that No liquid needed to administer Lightweight and easy to cannot swallow pills Optimized for palatability store and transport © 2018 CURE Pharmaceutical WHY CUREfilm™ IS BETTER

Capsule Liquids & & Chewables Sublingual CUREfilm™ Tablets & Melts Drops Powders

Ease of use for improved adherence No need for water, palatable ✓ ✗ ✓ ✓ ✗

Greater bioavailability – Fast acting, less active needed, less side effects ✓ ✗ ✗ ✗ ✓

Precision Dosing ✓ ✗ ✗ ✓ ✗

Transportation efficiency – No spillage, damage stability at room temperature ✓ ✓ ✗ ✓ ✗

MORE ACTIVE MULTIPLE TASTE INGREDIENT ACTIVES MASKING

We can load more active We can load multiple CUREfilm™ Oral has ingredient on a single actives on a single better taste-masking and CUREfilm™ Oral at CUREfilm™ Oral at overall mouth feel commercial scale commercial scale

(>200mg @ commercial scale)

INNOVATION & INTELLECTUAL VERTICALLY TECHNOLOGY PROPERTY INTEGRATED PORTFOLIO OPERATIONS

We maintain our competitive advantage by: continually improving our technology, implementing a thoughtful IP strategy and tightly controlling the quality and efficiency of our processes with integrated research and manufacturing operations.

A blended strategy of patents, trade secrets and proprietary equipment design.

CURE’S IP PORTFOLIO COMPONENTS:

• Film compositions 10 • Polymer blends ISSUED PATENTS • Encapsulation methods • Cannabinoid extraction and formulation methods 12 • Taste formulations PATENTS PENDING • Process engineering • Packaging

MARKET R&D / SCIENCE / MANUFACTURING FACILITY FEASIBILITY FORMULATION FEASIBILITY ● cGMP state-of-the-art 25,000 sq ft production plant in Oxnard, CA ● FDA-registered and audited facility ● Class 100,000 CRT humidity-controlled clean room environment PROCESS PACKAGE DESIGN ● Pharmaceuticals, controlled DEVELOPMENT & BRANDING substances (DEA schedule 1 manufacturing license) ● Expansion capability ● Custom drug delivery systems developed in a design control process

Goal: Improve PK Profile

Rabbit study comparing plasma concentration over time of 81mg aspirin formulated in a CUREfilm™ Oral vs Cmax 2x increase tablet >AUC and ½ life Result: CUREfilm™ Oral formulation lead to faster onset (Tmax) and better bioavailability (Cmax and AUC)

Tmax = 15 min (vs 30 min)

Goal: Bioequivalency

Rabbit study comparing plasma concentration over time of Artelutrine (2 drug combo) formulated in a CUREfilm™ Oral vs. COARTEM Dispersible Tablets

Result: CUREfilm™ Oral formulation lead to equivalent Tmax, Cmax and AUC

Goal: Evaluate bioavailability of non-optimized CUREfilm™ Transdermal formulations for a large range of molecular sizes and spatial configurations

Ex-vivo study using human tummy tuck tissue to assess the transdermal delivery of various actives in gel format.

Result: Non-optimized CUREfilm™ can deliver a variety of actives through the most impermeable tissue membrane: the skin. This data supports our ability to deliver actives across the more vascularized oral mucosal membrane.

Goal: Facilitate small animal research by offering an alternative to oral gavage

Ivermectin mouse study at the USC Department of Pharmacology using CUREdots™, an oral CUREfilm™ designed for administration to small animals

Result: With CUREdots, there is no trauma to the animal as compared to oral gavage which affects intake (placebo – fig 1) leading to a more accurate efficacy study.

Fig. 1 Administration through Gavage Fig. 2 Administration with CUREdots

+++

We employ a three-pronged approach to market penetration:

1 2 3 NUTRACEUTICALS PHARMACEUTICALS CANNABINOIDS

● No FDA approval required ● Greater impact for patients ● Improve bioavailability of ● Faster and cheaper to launch ● Longer development time and cost cannabinoids to increase efficacy of than drugs but better pricing these promising molecules ● White labeled and distributed ● Diversified go-to-market strategies ● Synthetic cannabinoid products by 3rd parties with focus on ANDA and 505(b)(2) developed in house ● Short term revenues approval pathway ● Licensed rights to Canopy ● Permits rapid optimization of ● Revenues from development fees, Growth for whole plant and production capabilities license fees, milestone payments, biosynthetic applications ● Drives innovative formulations manufacturing fees and royalties. ● Collaboration with Technion with higher doses of API Institute in cancer © 2018 CURE Pharmaceutical PIPELINE

Formulation Manufacturing Clinical Launch Development Scale Up Trials

CUREfilm™ SLEEP

CUREfilm™ BLUE

CUREfilm™ D

CUREfilm™ β-CARYOPHYLLENE

Canopy CUREfilm™ pipeline

CUREfilm™ Canna

KEY Nutraceutical Pharmaceutical Cannabinoids NUTRACEUTICALS: CUREfilm™ SLEEP

MARKET PRODUCT PRODUCT POTENTIAL DIFFERENTIATION STATUS

● Convenient thin ● Launched 2017 film dosage form • ID LIFE $1.5B ● Scientifically ●Launched 2018 proven CUREfilm™ • SLEEP STRIPZZZ formulation Melatonin supplement ●Potential for platform sales reached $851 additional distributors ● Patent pending million in 2016 and combination of projected to top $1.5 ingredients that Two different melatonin- billion by 2021* promote both sleep based daily dietary and recovery supplements to promote ● cGMP facility and healthy sleep patterns processes

MARKET PRODUCT PRODUCT POTENTIAL DIFFERENTIATION STATUS

● Faster onset ● Manufacturing $3.5B ● Ease of dosing scale up ● Discreet with no ● 505(b)(2) pathway Market is expected to water needed in US grow exponentially ● Breath freshening ● Exclusive over the next 10 partnership for years. distribution in ASEAN territories Patent expiration and ● US launch in 2021 availability of the drug 50mg of Sildenafil in various dosage forms will help grow the market.

MARKET PRODUCT PRODUCT POTENTIAL DIFFERENTIATION STATUS

● Weekly dose ● Manufacturing ● Vitamin D3 - the scale up $2.5B physician ● Exclusive recommended form partnership for of Vitamin D distribution in MENA Vitamin D ● Convenient thin film territories supplementation is dosage form ● Projected launch projected to reach ● Scientifically proven 2019 $2.5 billion by 2020* CUREfilm™ 50,000 IU of Vitamin D3 formulation platform delivered with the ● cGMP facility and CUREfilm™ platform as a processes high potency supplement.

MARKET PRODUCT PRODUCT POTENTIAL DIFFERENTIATION STATUS

● No solid dosage ● Formulation $261M forms currently on optimization Anti-inflammatory the market ● Projected launch supplementation with ● Scientifically proven 2019 turmeric (curcimin) in CUREfilm™ ● Seeking distribution 2016* formulation platform partners ● cGMP facility and processes $25B ● Non GMO, Gluten Contains 30mg of β Immune health Free Caryophyllene, an supplementation is inflammation-fighting and projected to reach $25 analgesic terpene. billion by 2025**

Robert Jessica Alex Katz Davidson CFO CEO Rousset COO

● Formerly founding partner of Katz and ● Formerly President and CEO of InnoZen ● Formerly Head of Innovation at Children’s Miele, LLP, CEO of Fastener Distribution Inc., CEO of Gel Tech LLC, CEO of Bio Hospital Los Angeles, licensing officer at The and Marketing Company, Inc., Chief Delivery Technologies Inc. Scripps Research Institute and held Financial Officer of Lenape Dynamic, Inc. ● Lead the development of several drug research, clinical and business development ● Serves as Managing Partner of a ff delivery technologies and commercial brand positions held at GlaxoSmithkline Venture Capital and Differential extensions including Chloraseptic™, Biologicals. Venture Partners and Director at Suppress™, as well as Pediastrip™, ● Founder and director of one of seven Eventus Advisory Group ● B.S. degree in Biological Life Sciences; national FDA-funded pediatric medical ● Bachelor of Science in Business Masters Certificate in Applied Project device accelerators. Administration from Drexel University, Management from Villanova University, ● Masters in Biochemical engineer at the Juris Doctor degree from Temple Masters of Public Health from American Institut National des Sciences Appliquées in University School of Law Military University, Virginia. Lyon, France. © 2018 CURE Pharmaceutical TEAM

Steven Vered Gary Paul Ruhl Gigi Speier Sudhakar VP, VP, Strategy IP Counsel Regulatory Manufacturing & Business Counsel Development

● Registered U.S. patent attorney and ● President and CEO of PTS Consulting, partner at Carlson Caspers. Over 25 LLC and has over 30 years of years experience in pharmaceutical experience in the pharmaceutical and ● Over 35 years of experience ● Formerly Project Leader with the patent law. related industries. leading technical teams. Boston Consulting Group focused ● JD - Temple University School of Law, ● Formerly held leadership positions at ● Amgen Thousand Oaks and on corporate and network MBA - University of Massachusetts, Midland Pharmaceutical, ratiopharm Ireland in multiple process strategy, operations, marketing Amherst, M.Sc. Chemistry - Villanova GmbH (now Teva), Martec Scientific development leadership roles. and post-merger integration University, B.Sc. Chemistry - Fordham (now Nostrum Lab) and Martec ● Management positions at initiatives. University. Pharmaceutical CancerVax, Certified Facilities, ● PhD in Immunology from the ● Admitted to the Supreme Courts of ● B.S. and M.S. in Pharmacy from the IDEC Pharmaceuticals, Xoma and University of Pennsylvania; BSc. MN, NJ, ND and PA, the U.S. District University Department of Chemical Court for the District of NJ, U.S. Court Technology, India, an M.B.A. from Celtrix Pharmaceuticals. in Bio-Medical sciences from of Appeals for the Federal Circuit and Andrews University, Michigan and ● Trained as microbiologist and Tel-Aviv University in Israel. the U.S. Patent and Trademark Office. Kansas State University, Kansas chemist at Brigham Young University. BOARD OF DIRECTORS

Gene Salkind, MD Alan Einstein, MD William Yuan (Chairman) ● Board certified in neurological surgery by the ● Grandson to famed Albert Einstein, has ● Chairman and CEO of Fortress Hill American Board of Neurological Surgery and been practicing medicine since 1996. Holdings, an Asian-based investment completed various residencies, fellowships and ● Assisted Senator David Shafer in the writing banking firm. postgraduate training at Abington Memorial hospital, and passage of Georgia’s first and only Cord ● 23 years in global finance experience. The Graduate Hospital, Veteran’s Administration Blood stem cell bill. ● Key strategist and advisor to international Hospital, Pennsylvania Hospital, Children’s Hospital ● Thought leader in the area of metabolic institutions. U.S. companies include Amgen of Philadelphia, and the Hospital of the University of syndrome and its role in weight gain and Corp., Biogen, GE Capital, Warner Brothers Pennsylvania. overall health and longevity. Studios, and Fox News. ● Guided leading Asian institutions like ● MD from Temple University School of Medicine and ● B.S. in Physical Chemistry from the Sina.com, Shanghai Petrochemicals, Jinlia his Bachelor of Arts from the University of University of Florida a medical degree from Pharmaceutical and Tsingtao Beer Corp. Pennsylvania. The College of Osteopathic Medicine and Led Merrill Lynch Asset Management Asia, ● Numerous faculty, hospital and administrative Surgery in Des Moines, Iowa, training at The ● Managed one of the largest pension / appointments at virtually every major hospital in the Johns Hopkins University School of retirement funds in the world, with a $488 northeastern Philadelphia and surrounding areas. Medicine/Sinai Hospital program in Internal billion portfolio. ● Prolific pharmaceutical investor including Intuitive Medicine, where he was recognized as, “The ● Member of the International Who’s Who of Surgical, Pharmacyclics, which grew from less than $1 Outstanding Senior Resident of the Year.” Finance, Technology, Media and Telecom. per share to subsequently being acquired by Abbvie for $250/share, and Centocor, acquired by Johnson & ● B.S. in Economics from Cornell University Johnson for $4.9 billion in stock. ● Attended as a Mason Fellow at Harvard ● Sits on the board of DermTech, a private company University’s John F. Kennedy School. based in San Diego that has become the global leader in non-invasive dermatological molecular diagnostics. ADVISORS

Michael Neely, MD Richard Serbin ● Director of the University of Southern California ● Global strategy advisor and entrepreneur with Laboratory of Applied Pharmacokinetics, which has been credentials both in pharmacy and law, complemented at the forefront of nonparametric population by more than 40 years of service as an FDA regulatory pharmacokinetic modeling techniques and dose attorney and consultant and patent attorney in the optimization for individual patients for over 35 years. healthcare industry. ● Associate Professor of Pediatrics, Clinical Scholar at the ● Pharmacist and patent attorney with more than 40 University of Southern California (USC) and at Children’s years of experience in the pharmaceutical industry and Hospital Los Angeles. the investment community. ● Research and clinical interests are in pediatric clinical ● COO of the Gorlin Companies, a family office focused pharmacometrics, including population pharmacokinetic on healthcare technologies, COO of Sapir and pharmacodynamic modeling, pharmacogenomics, Pharmaceuticals, an early stage pharmaceutical simulation, and most importantly, use of models to company with offices in the US and France. optimize therapy for individual patients. ● Has held senior positions at Schering-Plough ● Member of the United States Food and Drug Corporation, Revlon Corporation and Johnson & Administration Anti-infective Drug Advisory Committee Johnson Corporation, and has been the founder or and board certified in pediatrics, pediatric infectious co-founder of over 10 healthcare technology and/or diseases and a Fellow of the American College of Clinical healthcare service organizations. Pharmacology. ● Sits on the Boards of several healthcare companies and on the Advisory Board of the Swedish American Life Science Summit. COMPANY DISCLAIMER

This Investor Presentation is supplied for informational purposes only and does not constitute (1) an offer to sell, or the solicitation of an offer to buy, any securities of CURE Pharmaceutical, or (2) a promise or representation that any such offer will be made to the recipient or any other party.

The offering is being made only to qualified investors. The offering shall be made pursuant to documents reasonably acceptable to the Company and the Investors, which agreements shall contain, among other things, (i) short form, basic representations and warranties by the Company, and (ii) covenants of the Company reflecting the provisions set forth herein and appropriate conditions of closing.

Documents to be drafted by counsel to the company. Read those documents before making an investment decision. The securities are being offered in reliance upon exemptions from registration under the Securities Act of 1993 and only in the states in which the offering of securities is registered or is exempt from registration and by broker-dealers authorized to do so. OTCQB: CURR

CURE Pharmaceutical Delivering the Promise of Healthier Lives

January 2019